The Alzheimer's brain tau pathology was not systematically assessed in the SMC participants, so the interpretation of the present longitudinal findings is limited to the interaction between educational attainment and amyloid‐related preclinical Alzheimer's pathology rather than targeting an overt preclinical AD status. The gene discussed is MAPT; the disease is Alzheimer disease.